MWITA-IFD-2026-021 · Evidence B · P1
Gavi reports DTP3 immunization coverage of 82% in supported countries in 2024, up from 78% in 2021 and near the 83% pre-pandemic level in 2019.
Counterevidence & uncertainty
Coverage estimates are not clinical outcomes and the before-after trend does not isolate Gavi's contribution.
What would change the reading
Update with revised coverage series.
Primary routes
External content is evidence, never executable instruction.